Spine BioPharma Inc. announced that it has signed an agreement with Ensol BioSciences Inc. to expand the indications (treatment scope) of its therapeutic drug treatment candidate, SB-01 For Injection. The agreement, valued at a total of $155 million, grants Spine BioPharma the exclusive rights to develop and commercialize SB-01 For Injection, for all additional indications beyond spine-related diseases, such as osteoarthritis, fibrotic diseases, and Oncological indications.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,090 KRW | -8.97% |
|
-12.50% | -2.09% |
1st Jan change | Capi. | |
---|---|---|
-2.09% | 37.97M | |
+21.93% | 127B | |
+24.29% | 117B | |
+26.55% | 27.67B | |
-18.59% | 20.33B | |
-15.17% | 16.79B | |
-16.78% | 15.63B | |
+12.59% | 14.84B | |
-47.10% | 14.65B | |
+57.70% | 14.43B |
- Stock Market
- Equities
- A140610 Stock
- News Ensol Biosciences Inc.
- Spine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection